Covexin 8 VaccineThis page contains information on Covexin 8 Vaccine for veterinary use.
The information provided typically includes the following:
- Covexin 8 Vaccine Indications
- Warnings and cautions for Covexin 8 Vaccine
- Direction and dosage information for Covexin 8 Vaccine
Covexin 8 VaccineThis treatment applies to the following species:
CLOSTRIDIUM CHAUVOEI-SEPTICUM-HAEMOLYTICUM-NOVYI-TETANI-PERFRINGENS TYPES C & D BACTERIN-TOXOID
Covexin 8 Vaccine Indications
For the vaccination of healthy cattle and sheep against diseases caused by Clostridium chauvoei, Cl. septicum, Cl. novyi Type B, Cl. haemolyticum (known elsewhere as Cl. novyi Type D), Cl. tetani and Cl. perfringens Types C and D.
Although Clostridium perfringens Type B is not considered a significant problem in the U.S.A., immunity may be provided against the beta and epsilon toxins elaborated by Cl. perfringens Type B. The immunity is derived from the combination of Type C (beta) and Type D (epsilon) fractions.
Administration And Dosage
Shake well. Using aseptic technique
Cattle dosage: Inject 5 mL subcutaneously or intramuscularly, repeated in 6 weeks. Revaccinate annually with 5 mL prior to periods of extreme risk or parturition. For animals subject to reexposure to Cl. novyi Type B and Cl. haemolyticum repeat the dose every 5 to 6 months. For Cl. perfringens Types B, C and D, revaccinate two weeks prior to parturition, introduction to lush pastures or finishing programs. Calves vaccinated under 3 months of age should be revaccinated at weaning or 4 to 6 months of age.
Sheep dosage: Inject 5 mL subcutaneously followed by a 2 mL dose in 6 weeks. Revaccinate annually with 2 mL prior to periods of extreme risk or parturition. For Cl. novyi and Cl. haemolyticum, revaccinate every 5 to 6 months. Vaccination should be scheduled so that pregnant ewes receive their second vaccination or annual booster 2 to 6 weeks before lambing commences in the flock. Lambs should be given their primary course beginning at 10 to 12 weeks of age.
This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy. This level of performance may be affected by conditions of use such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.
Local reactions may be observed following subcutaneous administration to cattle.
Covexin 8 Vaccine Caution
Store at 35°-45°F (2°-7°C). Protect from freezing. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Anaphylactic reactions may occur following use.
Manufactured by SCHERING-PLOUGH ANIMAL HEALTH LIMITED, UPPER HUTT, NEW ZEALAND
Distributed by SCHERING-PLOUGH ANIMAL HEALTH CORP., OMAHA, NE 68103 U.S.A.
U.S. Veterinary Permit No. 311
FOR VETERINARY USE ONLY
Copyright © 1997 Schering-Plough Animal Health Corp.
Omaha, NE 68103 U.S.A.
Covexin 8 is a registered trademark of Schering-Plough Animal Health Corporation.
NAC No.: 10470332
556 MORRIS AVE., SUMMIT, NJ, 07901
|Technical Service (Companion Animal):||800-224-5318|
|Technical Service (Livestock):||800-211-3573|
|Every effort has been made to ensure the accuracy of the Covexin 8 Vaccine information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-05-31